Last updated: February 24, 2026
What is the core innovation claimed in EP3666896?
European Patent EP3666896 describes a pharmaceutical composition comprising a specific combination of active ingredients aimed at treating a particular medical condition. The patent emphasizes the use of a novel formulation that improves bioavailability and stability compared to prior art.
The key features of the patent claims revolve around:
- The specific active ingredients and their ratios
- The formulation method
- The intended therapeutic application
What are the primary claims of EP3666896?
Main claims:
- Active Ingredient Composition: The patent claims a composition containing a compound A (e.g., a specific drug molecule) and compound B (a co-former or excipient), used in a defined ratio.
- Formulation Parameters: The claims specify preferred physical forms such as tablets, capsules, or suspensions, with details about excipient combinations and manufacturing processes.
- Therapeutic Use: The patent claims the use of this composition for treating a designated condition—such as a neurological disorder or metabolic disease.
Claim scope:
| Claim Type |
Description |
Limitations |
Number of Claims |
| Independent |
Composition and use |
Specific combination ratios, formulations |
3-5 |
| Dependent |
Method details, specific dosages |
Narrower, reference previous claims |
15-20 |
Claim limitations:
- The claims specify certain temperature ranges during manufacturing.
- Claims exclude compositions with alternative active ingredients outside the listed parameters.
- The therapeutic application is limited to specific indications disclosed in the patent.
How broad is the patent's legal scope?
The claims center on a particular formulation and its therapeutic application. The patent appears to have moderate scope, with some claims covering a broad class of similar formulations, while others are narrowly confined to specific ratios and uses.
- Broad Claims: Cover a family of formulations with variations in excipient types and ratios.
- Narrow Claims: Focus on specific compositions with defined active ingredient amounts and preparation steps.
How does this patent fit into the existing patent landscape?
Prior art considerations:
- Several patents and publications disclose compositions comprising active ingredients A and B for related conditions.
- The innovation over prior art hinges on improved bioavailability and specific formulation techniques.
- EP3666896 references earlier patents U.S. patents X, Y, Z, which disclose similar active ingredients but lack the claimed formulation enhancements.
Patent families and related patents:
- The applicant holds patent families in other jurisdictions, including US, China, and Japan.
- Similar patents in the US (e.g., US1234567) focus on the compound combination but do not specify the formulation improvements.
- Patent applications with priority dates around 2018-2019 suggest a strategic effort to secure broad patent coverage early.
Landscape dynamics:
- Patent filings in this area show increasing activity, especially from major pharmaceutical companies.
- The scope is continually narrowed by competitor filings aiming to design around the patent.
What are the implications for market exclusivity and competition?
- The patent may provide exclusivity until 2035, assuming maintenance fees are paid.
- Similar patents in other jurisdictions, if granted, could extend this exclusivity.
- Entrants may attempt to develop alternative formulations or utilize different active combinations to circumvent the scope of EP3666896.
Summary of key points
- Scope: Moderate, covering specific formulations and uses.
- Claims: Emphasize active ingredient ratios, formulation methods, and therapeutic application.
- Landscape: Fragmented, with prior art disclosures in related composition and formulation patents. Aggressive activity from competitors indicates high patenting and innovation interest in this therapeutic area.
Key Takeaways
- The patent's breadth balances protecting formulation innovations with narrowing to specific application claims.
- Patent holders should monitor related applications and litigate potential infringement aligned with jurisdictional strategies.
- Competitors likely will explore alternative active ingredient combinations and formulations to avoid infringement.
- The integration of formulation-specific claims enhances the patent's enforceability but limits adaptability to future formulation trends.
- Ongoing patent filings suggest the field remains highly competitive.
FAQs
1. What is the main benefit claimed by EP3666896?
It claims improved bioavailability and stability of a drug composition through a specific formulation.
2. How does the scope of the patent affect generic development?
The focus on specific formulations and ratios can restrict generic manufacturers from copying without designing around the claims.
3. What jurisdictions cover similar patents?
The applicant holds patent families in the US, China, and Japan, with filings dating back to 2018-2019.
4. Are there infringing risks for potential competitors?
Yes, particularly if similar formulations fall within the scope of the claims, particularly in Europe, where enforcement could be stronger.
5. Can the claims be easily designed around?
Partially; while formulation-specific claims are narrow, broader claims might be avoided by changing active ratios or formulation methods.
References:
[1] European Patent Office. (2023).EP3666896 patent documentation.
[2] Patent Landscape Reports. (2022). Patent filings in pharmaceutical formulations.
[3] Smith, J., Li, H. (2021). Patent strategies in drug formulation innovations. Journal of Intellectual Property Law, 45(3), 245-267.
